Pulmatrix (NASDAQ:PULM) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Friday morning. The firm issued a hold rating on the biotechnology company’s stock.

Pulmatrix Price Performance

NASDAQ PULM opened at $6.00 on Friday. Pulmatrix has a one year low of $1.55 and a one year high of $8.44. The firm has a market cap of $21.91 million, a P/E ratio of -2.27 and a beta of 1.54. The stock’s 50-day moving average is $4.28 and its 200-day moving average is $2.84.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.